ANESTAGEL™

A NEW, OPIOID-FREE PAINKILLER

  • Non-opioid painkiller – pre-clinical stage
  • Lasts up to 300% longer than leading competitor*
  • 22 U.S. Patents
Learn More About Investing

WHO WE ARE

InSitu Biologics is an emerging biotech company focusing on development of AnestaGel™, a long-lasting and long-acting non-opiate painkiller. The sustained release drug AnestaGel is expected to be used in post-operative surgical procedures. AnestaGel may be a solution in relieving pain for broken bones, cosmetic surgery, hip/knee replacements, hernia, and more. For an in-depth look at our plans, audited financials, and other company information please read our Regulation A+ approval issued by U.S. Securities and Exchange Commission (SEC).

ABOUT ANESTAGEL™

  • AnestaGel™

    • InSitu Biologics' lead product, AnestaGel™, is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management.

    • 22+ US Patents Issued, with matching OUS positions
    • Hydrogel technology licensed from Cleveland Clinic Foundation
    • Tunable, biocompatible, and pH neutral platform
    • High dose drug-load reservoir capacity with a predictable pharmacological effect
    • Non-opioid pain relief option

    Pre-Clinical Results

    As compared to EXPAREL (Pacira, Inc.), the industry leading post-operative pain treatment.

    300% Longer

    Initial animal study revealed AnestaGel™ lasted up to 300% longer

    8x More Capacity

    AnestaGel™ carried 8 times more payload

    72+ Hours

    AnestaGel™ had full nerve block beyond 72 hours

    Timeline

    • 2015

      Q1
      Defined the Matrix and AnestaGel

      Q2
      Raised $1 million

      Q3
      Completed first pre-clinical study

      Q4
      Analysis showed statistical success compared to Exparel

    • 2016

      Q1
      Filed additional patent(s)

      Q2
      White Paper published

      Q3
      Completed maximum dosing study with no toxicity

      Q4
      Presented at PODD-Boston

    • 2017

      Q1
      Completed first GLP study

      Q2
      Proved more pain relief compared to Exparel in pre-clinical study

      Q3
      GLP publication accepted

      Q4
      Raised over $400k

    • 2018

      Q1
      Completed Financial Audit
      Converted all debt
      Filed $10,000,000 RegA+ Offering

      Q2
      Launch RegA+ Offering
      Announce GLP Paper by Hutchins & Taylor

      Q3
      Announce final GLP Study results
      Begin Phase 1 manufacturing

      Q4
      Expect approval for Phase 1 Clinical Study of AnestaGel

    The Team

    Meet the InSitu Biologics Team

    James Segermark

    CEO

    Jim has been the founder, inventor, investor, and owner operator in many med-tech ventures. Jim began working on the Matrix technology in 2007 and co-founded InSitu Biologics in 2014. Jim is an inventor on over 40 issued patents for medical products, and specializes in the total enterprise of bringing proprietary products from “just an idea” through design, scaled up manufacturing, and “to the patient”. Jim earned his Bachelor of Science from Carroll University in Waukesha, Wisconsin and his MBA from Cardinal Stritch University in Milwaukee.

    Bill Taylor

    Chief Scientist

    Bill is a Co-Founder of InSitu Biologics, beginning his work on the Matrix in 2007. Bill is a successful medical product development programs manager and scientist, and has been awarded over $900k in government research grants, and authored industry papers in chemical remediation and demilitarization utilizing biological systems. Bill has his Bachelor of Science from the University of Minnesota with a double major in Chemical Engineering and Biology.

    Daniel Sipple

    DO Medical Advisor

    Dr. Dan is a Co-Founder of InSitu Biologics, and a physiatrist that specializes in the diagnosis, treatment and rehabilitation of a variety of musculoskeletal and pain disorders, with an emphasis on spine care. Dan performs numerous interventions, including epidural steroid injections, radiofrequency, spinal cord stimulation and ultrasound guided procedures. A graduate of the University of Minnesota, Dan attended medical school at Des Moines University, doing his internship at the University of Massachusetts Medical Center and residency at the Rehabilitation Institute of Chicago. Dr. Sipple completed his fellowship training in interventional pain medicine through Sinai Hospital of Baltimore, MD. Dan is an inventor and co-inventor on multiple medical products.

    Jacob Hutchins

    MD Medical Advisor

    Jake was the Principal Investigator for the InSitu GLP Study comparing AnestaGel™ to Exparel, and Jake is the Director of the Regional Anesthesia Acute Pain and Ambulatory Surgery division at the University of Minnesota. Jake is also the medical director for the M Health Ambulatory Surgery Center. His current research interests include ultrasound-guided regional anesthesia in adult and pediatric acute postoperative pain as well as ambulatory anesthesia. His research also involves the use of liposomal bupivacaine for postoperative pain control in a variety of surgical procedures. Jake is a life-long Minnesota native and a graduate of the University of Minnesota Medical School, 2007.